Previous close | 215.01 |
Open | 215.50 |
Bid | 215.20 x 800 |
Ask | 218.28 x 900 |
Day's range | 213.22 - 218.25 |
52-week range | 132.24 - 237.26 |
Volume | |
Avg. volume | 1,114,903 |
Market cap | 32.048B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 33.61 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.92 (0.89%) |
Ex-dividend date | 08 May 2024 |
1y target est | N/A |
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.